Jennison Associates LLC Acquires 335,942 Shares of Sionna Therapeutics, Inc. $SION

Jennison Associates LLC lifted its holdings in Sionna Therapeutics, Inc. (NASDAQ:SION) by 30.1% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,451,220 shares of the company’s stock after acquiring an additional 335,942 shares during the period. Jennison Associates LLC’s holdings in Sionna Therapeutics were worth $58,179,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of the business. GF Fund Management CO. LTD. acquired a new stake in Sionna Therapeutics in the 4th quarter worth about $36,000. Russell Investments Group Ltd. bought a new stake in Sionna Therapeutics in the 3rd quarter valued at about $30,000. Balyasny Asset Management L.P. acquired a new position in shares of Sionna Therapeutics during the 4th quarter worth approximately $58,000. BNP Paribas Financial Markets bought a new position in shares of Sionna Therapeutics during the second quarter worth approximately $31,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Sionna Therapeutics during the fourth quarter worth approximately $89,000.

Sionna Therapeutics Stock Performance

Shares of Sionna Therapeutics stock opened at $49.41 on Monday. The company has a 50 day moving average of $40.74 and a 200-day moving average of $39.61. Sionna Therapeutics, Inc. has a 1-year low of $16.38 and a 1-year high of $51.00. The company has a market cap of $2.23 billion, a PE ratio of -25.60 and a beta of 1.33.

Sionna Therapeutics (NASDAQ:SION) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.52) by ($0.08). Research analysts forecast that Sionna Therapeutics, Inc. will post -2.57 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on SION. Freedom Capital cut Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, May 20th. BTIG Research restated a “buy” rating and set a $58.00 price objective on shares of Sionna Therapeutics in a research note on Wednesday, May 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sionna Therapeutics in a report on Friday, May 8th. Citizens Jmp reiterated a “market outperform” rating and set a $63.00 target price on shares of Sionna Therapeutics in a research report on Tuesday, May 26th. Finally, JonesTrading increased their target price on Sionna Therapeutics from $52.00 to $63.00 and gave the stock a “buy” rating in a report on Tuesday, April 28th. Three research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $53.22.

Insider Buying and Selling at Sionna Therapeutics

In other news, Director Orbimed Advisors Llc sold 85,918 shares of the business’s stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $44.86, for a total transaction of $3,854,281.48. Following the completion of the transaction, the director owned 2,469,959 shares of the company’s stock, valued at approximately $110,802,360.74. The trade was a 3.36% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter A. Thompson sold 85,918 shares of the company’s stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $44.86, for a total value of $3,854,281.48. Following the sale, the director owned 2,469,959 shares of the company’s stock, valued at approximately $110,802,360.74. This represents a 3.36% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 989,630 shares of company stock valued at $44,987,483 over the last 90 days. Corporate insiders own 5.10% of the company’s stock.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.